How to continue Strattera after moving to California

If you’ve been struggling with ADHD symptoms but worry about the complexities of getting treatment—or have concerns about stimulant medications—you’re not alone. Many people wonder: Can I get ADHD medication through a telehealth visit? What about non-stimulant options like Strattera?

The short answer is yes. Telehealth has opened new doors for ADHD treatment, especially for non-stimulant medications. But the landscape of telehealth prescribing is more nuanced than many realize, with federal and state regulations that affect what your provider can prescribe and how.

This comprehensive guide will walk you through everything you need to know about accessing ADHD non-stimulant medications via telehealth in 2025—from understanding which medications qualify, to navigating state-specific rules, to knowing what to expect from your virtual appointment.

Understanding ADHD Non-Stimulant Medications

What Are Non-Stimulant ADHD Medications?

Non-stimulant ADHD medications work differently than traditional stimulants like Adderall or Ritalin. The most commonly prescribed non-stimulant is Strattera (atomoxetine), though others include Intuniv (guanfacine) and Kapvay (clonidine).

Strattera is not a controlled substance—a crucial distinction that dramatically affects how it can be prescribed via telehealth. The FDA and DEA do not classify it as a Schedule II drug, meaning it doesn’t carry the same regulatory restrictions as stimulant medications. This makes Strattera more accessible through telehealth platforms and allows for greater prescribing flexibility.

How Strattera Works

Unlike stimulants that increase dopamine and norepinephrine levels immediately, Strattera is a selective norepinephrine reuptake inhibitor (SNRI). It works gradually by increasing norepinephrine availability in the brain, which helps with attention, impulse control, and executive function.

Key characteristics of Strattera include:

• Non-habit-forming: No potential for abuse or dependency
• Gradual onset: Takes 4-6 weeks to reach full therapeutic effect
• 24-hour coverage: Provides consistent symptom management throughout the day
• No DEA restrictions: Can be prescribed with refills and longer supplies (up to 90 days)

Who Might Benefit from Non-Stimulants?

Non-stimulant medications are particularly valuable for people who:

• Have a history of substance abuse or are at risk for medication misuse
• Experience significant side effects from stimulants (anxiety, sleep problems, appetite loss)
• Have comorbid conditions like anxiety disorders or tic disorders that stimulants might worsen
• Have cardiovascular concerns that make stimulants risky
• Prefer a medication with consistent, around-the-clock coverage
• Want to avoid the monthly prescription requirements of controlled substances

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

The Telehealth Advantage for ADHD Treatment

Current Federal Regulations (As of December 2025)

The regulatory landscape for telehealth ADHD treatment has evolved significantly since the COVID-19 pandemic. Here’s what you need to know about current federal rules:

For Non-Stimulant Medications (like Strattera):

• No federal restrictions on telehealth prescribing
• No requirement for an initial in-person visit
• Standard medical evaluation via video visit is sufficient
• These rules have been consistent and are not subject to the temporary waivers affecting controlled substances

For Stimulant Medications (like Adderall, Ritalin):

• Currently allowed through temporary DEA flexibilities extended through December 31, 2025
• The Ryan Haight Act normally requires an in-person exam before prescribing controlled substances online, but this requirement has been waived during the public health emergency extensions
• A fourth extension for 2026 is anticipated but not yet finalized
• If waivers expire without replacement, in-person exam requirements could resume

This distinction is critical: Strattera’s non-controlled status means it’s not subject to the regulatory uncertainty affecting stimulant medications. You can access it via telehealth with confidence that current rules won’t suddenly change.

Why Telehealth Works for ADHD Care

Telehealth offers several advantages for ADHD treatment:

Accessibility: Many people, especially in rural areas or with demanding work schedules, struggle to find local ADHD specialists. Telehealth expands your options beyond geographic limitations.

Continuity of care: Regular check-ins become easier when you can schedule appointments during lunch breaks or from home, improving medication management and treatment adherence.

Reduced stigma: Some patients feel more comfortable discussing mental health concerns from the privacy of their own space.

Cost-effectiveness: Telehealth visits often cost less than in-person appointments, and you save time and money on travel.

Comprehensive documentation: Digital platforms typically maintain thorough records of your treatment history, making it easier to track symptoms and medication responses.

At Klarity Health, we’ve designed our platform specifically to address these advantages while maintaining the highest standards of care. Our providers are licensed in your state, accept both insurance and cash pay, and offer transparent pricing—so you know exactly what to expect before your first appointment.

State-by-State Variations: What You Need to Know

While federal law governs the basics of controlled substance prescribing, state laws add another layer of complexity. The good news? No state outright bans telehealth treatment for ADHD. However, requirements vary significantly.

States with No Additional Telehealth Restrictions

California, Illinois, Pennsylvania: These states embrace telehealth and impose no extra in-person visit requirements for ADHD treatment. A comprehensive video evaluation satisfies the standard of care for prescribing non-stimulant medications.

Key considerations:

• Your provider must be licensed in your state
• Video (not just phone) is typically required for initial evaluations
• Standard medical documentation and diagnostic criteria still apply

States with Specific Requirements

New York: In May 2025, New York implemented rules requiring an initial in-person evaluation before prescribing any controlled substance via telemedicine. However, this does not affect Strattera or other non-controlled medications, which can still be prescribed purely via telehealth.

Alabama: Requires an in-person visit within 12 months for ongoing telehealth treatment—but makes an exception for mental health services. Since ADHD falls under mental health care, this requirement typically doesn’t apply to psychiatric ADHD treatment.

New Hampshire: Updated its laws in August 2025 to remove prior in-person requirements, now only requiring at least an annual follow-up evaluation (which can be conducted via telehealth) for controlled medication prescribing.

Florida: Generally prohibits telehealth prescribing of Schedule II stimulants unless it’s for a psychiatric condition (ADHD qualifies). Strattera, being non-controlled, faces no special restrictions in Florida.

Texas: Very telehealth-friendly for mental health care, with no blanket in-person requirement for ADHD treatment. However, Texas limits nurse practitioners and physician assistants from prescribing Schedule II stimulants except in hospital or hospice settings.

Understanding Provider Licensing

Regardless of state-specific rules, your telehealth provider must be licensed in the state where you’re physically located during the appointment. This means:

• A California-licensed provider cannot treat you if you’re in Texas
• If you move states, you may need to transition to a new provider
• Multi-state platforms like Klarity maintain networks of providers across state lines to ensure continuity

What to Expect from Your Telehealth ADHD Evaluation

The Comprehensive Assessment Process

Legitimate telehealth ADHD evaluations are thorough and evidence-based. Don’t expect a quick questionnaire followed by an automatic prescription—that’s a red flag for potentially unsafe ‘pill mill’ operations.

A proper evaluation includes:

Detailed symptom assessment: Your provider will ask about ADHD symptoms across multiple settings (work, school, home, relationships). They’ll use DSM-5 diagnostic criteria, which require evidence of symptoms in at least two settings and onset before age 12.

Medical history review: Expect questions about:

• Previous ADHD diagnoses or treatments
• Other mental health conditions (anxiety, depression, bipolar disorder)
• Medical conditions affecting heart, liver, or blood pressure
• Current medications and supplements
• Substance use history
• Family history of ADHD and mental health conditions

Functional impairment evaluation: Your provider needs to understand how ADHD symptoms impact your daily life—missing deadlines, relationship conflicts, job performance issues, or safety concerns like car accidents.

Rating scales and questionnaires: Many providers use standardized tools like the Adult ADHD Self-Report Scale (ASRS) or Conners rating scales to quantify symptoms.

Collateral information: For some patients, especially younger adults, providers may request input from family members, review old report cards, or contact previous treatment providers to confirm symptom history.

Documentation You May Need

Come prepared with:

• Photo ID and insurance information (if applicable)
• List of current medications and dosages
• Previous medical or psychiatric records, if available
• School records showing childhood symptoms (if seeking initial diagnosis)
• Contact information for your primary care provider

Safety Screening

Your provider will screen for conditions that might make ADHD medication unsafe or require in-person evaluation:

For Strattera specifically:

• Narrow-angle glaucoma (contraindication)
• MAOI antidepressant use within past 14 days
• Severe liver disease
• Uncontrolled high blood pressure or heart disease
• History of severe allergic reactions to atomoxetine

General ADHD treatment contraindications:

• Active substance abuse (may require stabilization first)
• Uncontrolled severe mental health conditions
• Recent suicidal ideation (Strattera carries FDA warnings about suicidal thoughts in youth)
• Certain cardiac conditions requiring specialist clearance

If your provider identifies safety concerns, they won’t simply deny treatment—they’ll discuss alternatives, recommend in-person follow-up with specialists, or suggest starting with therapy and lifestyle modifications while medical issues are addressed.

The Prescription Process: From Evaluation to Pharmacy

How E-Prescribing Works

Once your provider determines that Strattera is appropriate, they’ll send an electronic prescription directly to your preferred pharmacy. E-prescribing is now standard practice and is actually required by law in many states for controlled substances (though Strattera isn’t controlled, most providers use e-prescribing for all medications for efficiency and accuracy).

Benefits of e-prescribing:

• Faster processing (prescription arrives before you leave your home)
• Reduced errors from illegible handwriting
• Integrated safety checks for drug interactions
• Easier refill management
• Enhanced security and tracking

Prescription Details for Strattera

Because Strattera is not a controlled substance, your provider has flexibility in prescribing:

Supply duration: Typically 30-90 days, depending on your insurance and stability on the medication

Refills: Can include multiple refills (often 5-11 months’ worth), eliminating the need for monthly appointments once stable

Dosage adjustments: Your provider can call in dose changes without requiring a new full evaluation

No special forms required: Unlike Schedule II medications that need special prescription pads or enhanced security measures in some states

Pharmacy Considerations

Most pharmacies readily fill telehealth prescriptions from licensed providers. However:

Insurance coverage: Verify that your insurance covers Strattera and whether your telehealth visit is covered. Klarity Health accepts both insurance and cash pay, offering transparency in pricing regardless of your coverage situation.

Generic vs. brand: Atomoxetine (generic Strattera) is widely available and usually much less expensive. Ask your provider to prescribe ‘atomoxetine’ rather than brand-name ‘Strattera’ unless there’s a specific reason for the brand.

Prior authorization: Some insurance plans require prior authorization for ADHD medications, even non-stimulants. Your telehealth provider’s office can typically handle this, though it may delay your prescription by a few days.

Pharmacy stock: While not as commonly stocked as stimulants, most pharmacies carry atomoxetine. If your pharmacy doesn’t have it, they can usually get it within 1-2 business days.

Monitoring and Follow-Up Care

What Happens After Your First Prescription

Starting any ADHD medication requires ongoing monitoring. Your telehealth provider will schedule follow-up appointments to:

Assess effectiveness: Strattera takes 4-6 weeks to reach full effect, so don’t expect immediate results like you might with stimulants. You’ll track symptom improvement using rating scales or functional measures (work productivity, relationship quality, task completion).

Monitor side effects: Common Strattera side effects include:

• Upset stomach or decreased appetite (usually temporary)
• Fatigue or drowsiness (especially in the first few weeks)
• Dry mouth
• Dizziness
• Sexual side effects (decreased libido or difficulty with arousal)

Check vital signs: Your provider will ask you to monitor and report blood pressure and heart rate, especially in the first few months. Some may recommend getting these checked at a local pharmacy or clinic.

Adjust dosage: Strattera is typically started at a low dose and gradually increased. Most adults end up on 80-100mg daily, but this varies based on response and side effects.

Frequency of Follow-Ups

Initial stabilization phase (first 2-3 months):

• Week 1-2: Check-in to assess initial tolerance
• Week 4-6: Evaluate early response and consider dose adjustment
• Week 8-12: Assess full therapeutic effect

Maintenance phase:

• Monthly check-ins for the first few months
• Every 3-6 months once stable
• As-needed appointments for concerns or life changes

Telehealth makes these frequent check-ins manageable, eliminating the need to take time off work or arrange transportation for brief medication management visits.

Combining Medication with Therapy

The most effective ADHD treatment typically combines medication with behavioral interventions. Your telehealth provider may recommend or facilitate:

• Cognitive-behavioral therapy (CBT) for ADHD
• ADHD coaching for organizational skills and time management
• Lifestyle modifications (sleep hygiene, exercise, nutrition)
• Workplace or educational accommodations

Many telehealth platforms, including Klarity Health, can coordinate these services, connecting you with therapists or coaches who specialize in adult ADHD.

Addressing Common Concerns and Misconceptions

‘Online ADHD Prescriptions Are Too Easy to Get’

This misconception stems from media coverage of certain questionable telehealth companies. Legitimate telehealth ADHD care requires the same rigorous evaluation as in-person treatment.

Reputable providers:

• Use evidence-based diagnostic criteria
• Require comprehensive video evaluations (not just questionnaires)
• Review medical history and screen for contraindications
• Coordinate with other healthcare providers
• Implement appropriate safeguards against misuse

The scrutiny following investigations into companies like Cerebral and Done has actually strengthened the telehealth industry. Providers now implement even stricter protocols, including treatment agreements, periodic drug screens for stimulants, and enhanced documentation requirements.

At Klarity Health, our providers follow the same diagnostic standards you’d receive from a specialist in a traditional office setting. We’ve designed our platform to prioritize patient safety while maintaining accessibility.

‘Non-Stimulants Don’t Really Work’

Many people assume stimulants are the only effective ADHD treatment. While stimulants do work faster and for a higher percentage of patients, non-stimulants like Strattera can be very effective, particularly for:

• Patients with coexisting anxiety (Strattera may help both conditions)
• Those who need 24-hour symptom coverage
• People concerned about abuse potential
• Patients who experienced problematic side effects from stimulants

Clinical studies show: About 60-70% of patients respond positively to Strattera, with significant improvement in ADHD symptoms. While this is somewhat lower than the 70-80% response rate for stimulants, it’s still substantial—and for some patients, Strattera works better than stimulants ever did.

The key is patience and proper dosing. Many people give up on Strattera after a week or two, before it has time to work. Telehealth follow-ups help ensure you stick with treatment long enough to experience the full benefits.

‘Telehealth Doctors Can’t Prescribe Controlled Medications’

This is false—telehealth providers with proper DEA registration can prescribe controlled substances, including ADHD stimulants, under current federal flexibilities (extended through December 31, 2025, with another extension anticipated for 2026).

However, this is subject to evolving regulations. The temporary nature of these rules creates some uncertainty for stimulant prescriptions, which is another reason why Strattera’s non-controlled status makes it a more stable option for telehealth treatment.

‘My Local Pharmacy Won’t Fill Telehealth Prescriptions’

This is largely a myth, though some pharmacies did increase scrutiny of telehealth stimulant prescriptions in 2023 amid the Cerebral/Done investigations.

For Strattera prescriptions:

• Pharmacies treat them like any other non-controlled medication
• Electronic prescriptions are standard and accepted
• The prescription doesn’t indicate whether your visit was telehealth or in-person

Tips for smooth pharmacy experiences:

• Use a consistent pharmacy for all prescriptions
• Provide your pharmacy with your telehealth provider’s contact information
• Choose a reputable telehealth platform (pharmacists may be more comfortable with established services)
• Be prepared to show ID when picking up any prescription

Special Populations and Considerations

Adolescents and Young Adults

Most telehealth platforms treat adults (18+) for ADHD medication management, though some work with older teens with parental involvement.

For patients under 18:

• Parental consent and often participation in the evaluation is required
• Some states have specific rules about treating minors via telehealth
• Initial in-person evaluation is often recommended for younger children
• FDA approval for Strattera starts at age 6, but telehealth may not be appropriate for very young children

College students often find telehealth particularly valuable, as they can access care without visiting campus health services and maintain treatment continuity when returning home for breaks.

Pregnancy and Breastfeeding

Strattera is FDA Pregnancy Category C, meaning potential risks aren’t fully known but should be weighed against benefits. If you’re pregnant, planning pregnancy, or breastfeeding:

• Inform your telehealth provider immediately
• Discuss risks and benefits of continuing medication
• Consider non-medication strategies for symptom management
• Your provider may recommend consultation with an OB-GYN or maternal-fetal medicine specialist

Telehealth can facilitate this coordination, with providers communicating to ensure all your doctors have a complete picture.

Patients with Coexisting Conditions

ADHD commonly occurs alongside:

• Anxiety disorders (40-50% of adults with ADHD)
• Depression (18-38%)
• Bipolar disorder (up to 20%)
• Substance use disorders
• Learning disabilities

Strattera may be particularly useful if you have both ADHD and anxiety, as it can help both conditions without the potential anxiety-worsening effects some stimulants cause.

However, complex psychiatric presentations may require in-person specialty care. Your telehealth provider should recognize when conditions are too complex for virtual management alone and coordinate appropriate referrals.

Patients Switching from Stimulants

If you’ve been on stimulant medications but want to try a non-stimulant:

Transition approaches vary:

• Some providers recommend a ‘cold turkey’ switch (stop stimulant, start Strattera)
• Others prefer overlapping treatment during the Strattera build-up period
• Timing should consider important life events (don’t switch right before a major work deadline)

Expect an adjustment period: Strattera feels different from stimulants. It won’t give you the immediate ‘focus boost,’ but many patients report more stable, consistent symptom management once it takes full effect.

Telehealth is ideal for transitions, as frequent check-ins during the switch help your provider adjust the approach based on your response.

Practical Tips for Successful Telehealth ADHD Treatment

Before Your First Appointment

Choose a reputable platform: Look for services that:

• Employ licensed clinicians (MD, DO, or NP/PA with appropriate credentials)
• Require video visits (not just questionnaires)
• Have clear policies about diagnosis and prescribing
• Are transparent about costs and insurance
• Mention evidence-based practices and DSM-5 criteria

Prepare your environment:

• Find a private, quiet space for your video visit
• Test your technology beforehand
• Ensure good lighting so the provider can see you clearly
• Have a notebook ready for questions and notes

Gather information:

• Medication list (including vitamins and supplements)
• Contact information for current providers
• Insurance card and ID
• Examples of how ADHD affects your daily life

Be honest and thorough: Your provider can only help if they have accurate information. Don’t minimize symptoms to seem ‘more functional’ or exaggerate to ensure getting medication. The goal is finding the right treatment for your actual needs.

During Treatment

Attend follow-up appointments: Even when you’re stable, regular check-ins ensure optimal treatment and catch any emerging issues early.

Track your symptoms: Keep notes about:

• Which symptoms improve and which persist
• Side effects and their severity
• How medication affects different areas of life (work, relationships, daily tasks)
• Any patterns (does effectiveness wear off at certain times?)

Communicate changes: If you start new medications, develop new health conditions, or experience major life stressors, inform your provider—these can all affect ADHD treatment.

Take medication consistently: Strattera requires daily use, even on weekends and vacations. Set reminders if needed (one of those ADHD management strategies your medication is helping you implement!).

Store medication properly: Keep it in a cool, dry place away from children and pets, even though it’s not a controlled substance.

Managing Practical Concerns

Prescription refills: Set calendar reminders to request refills with enough lead time to avoid running out. Most platforms allow refill requests through patient portals.

Insurance changes: If your insurance changes, contact your telehealth provider’s office immediately to update information and verify continued coverage.

Travel considerations:

• Strattera can be carried in carry-on luggage without special documentation
• If traveling internationally, check destination country’s regulations
• Bring enough medication to cover your trip plus a few extra days

Cost management:

• Ask about generic options (atomoxetine vs. brand Strattera)
• Check if your insurance offers mail-order pharmacy discounts for 90-day supplies
• Inquire about patient assistance programs if costs are prohibitive
• Klarity Health offers transparent pricing and accepts both insurance and cash pay, helping you understand costs upfront

When Telehealth Isn’t the Right Fit

Consider seeking in-person care if:

• You have complex medical conditions requiring extensive physical examination
• You have severe, unstable mental health conditions
• Your provider recommends in-person specialty consultation
• You feel uncomfortable with the virtual format
• Your symptoms aren’t improving and the provider can’t determine why remotely

Telehealth and in-person care aren’t mutually exclusive. Many patients use a hybrid approach—initial assessment and ongoing medication management via telehealth, with periodic in-person visits to their primary care provider or specialists as needed.

Looking Ahead: The Future of Telehealth ADHD Treatment

Regulatory Outlook for 2026 and Beyond

The telehealth landscape continues to evolve. Here’s what to watch:

Federal level:

• The DEA is developing a permanent framework for controlled substance prescribing via telehealth, possibly requiring special registration
• A fourth extension of COVID-era flexibilities for 2026 is anticipated but not yet finalized
• Congressional bills like the TREATS Act could expand cross-state telehealth practice
• For Strattera and non-controlled medications, no changes are expected—these remain fully accessible via telehealth

State level:

• More states are moving toward permanent telehealth parity laws
• Stricter PDMP requirements and e-prescribing mandates continue to expand
• Some states are enhancing NP/PA prescribing authority while others maintain restrictions

What this means for patients:

• Non-stimulant telehealth treatment (like Strattera) will likely remain stable and accessible
• Stimulant prescribing may require periodic in-person visits in the future
• Staying connected with a reputable platform ensures you’ll be guided through any transitions

Emerging Best Practices

The industry is moving toward:

Hybrid care models: Combining telehealth convenience with periodic in-person touchpoints for comprehensive assessment

Enhanced coordination: Better integration between telehealth providers, primary care doctors, therapists, and specialists

Technology integration: Apps for symptom tracking, medication reminders, and real-time provider communication

Evidence-based protocols: Standardized assessment tools and treatment algorithms ensuring consistent, high-quality care

The Role of Patient Advocacy

As telehealth ADHD treatment matures, patient voices matter:

• Share your experiences with telehealth platforms to help them improve
• Participate in surveys or research about telehealth effectiveness
• Advocate for policies that maintain access while ensuring safety
• Support organizations working to reduce ADHD stigma and improve care access

Making the Decision: Is Telehealth Right for Your ADHD Treatment?

The Benefits Recap

Telehealth ADHD treatment offers:

• Accessibility regardless of location
• Scheduling flexibility around work and life demands
• Often lower costs than traditional in-person care
• Reduced stigma and increased privacy
• Easier ongoing medication management
• Access to specialists who might not practice in your area

For non-stimulant medications like Strattera:

• No regulatory uncertainty
• Flexible prescribing options (refills, longer supplies)
• No controlled substance restrictions

Potential Limitations

Telehealth may not be ideal if you:

• Strongly prefer face-to-face interaction
• Have complex medical conditions requiring physical examination
• Need extensive coordination between multiple specialists
• Have severe psychiatric instability requiring in-person crisis management
• Lack reliable internet access or appropriate technology

Taking the Next Step

If you’re ready to explore telehealth ADHD treatment:

1. Research reputable platforms: Look for providers like Klarity Health that prioritize comprehensive evaluation, licensed providers, and transparent practices

2. Check your insurance coverage: Understand what’s covered and any out-of-pocket costs

3. Prepare for your evaluation: Gather documentation and think through your symptom history

4. Be open to the process: Trust that a thorough evaluation, even virtually, can lead to effective treatment

5. Commit to follow-up: ADHD management is ongoing—stay engaged with your provider

Conclusion: Access Meets Quality in Modern ADHD Care

The expansion of telehealth has genuinely transformed ADHD treatment access. For non-stimulant medications like Strattera, telehealth removes many traditional barriers while maintaining high standards of care.

You don’t have to choose between convenience and quality. With the right telehealth provider, you can access comprehensive ADHD evaluation and treatment from wherever you are—during your lunch break, after putting kids to bed, or from the privacy of your home.

The key is choosing a platform that does it right: licensed providers, evidence-based practices, thorough evaluations, ongoing monitoring, and transparent policies. When telehealth is done well, it’s not a lesser alternative to in-person care—it’s simply a different format for delivering the same high-quality, patient-centered treatment.

If you’ve been putting off seeking ADHD treatment because of scheduling challenges, lack of local specialists, or concerns about stimulant medications, telehealth with non-stimulant options like Strattera might be exactly what you need.

At Klarity Health, we’ve built our platform around these principles. Our providers are available when you need them, our pricing is transparent, we accept both insurance and cash pay, and we’re committed to comprehensive, evidence-based ADHD care. Whether you’re seeking an initial evaluation or looking to transition from in-person care to a more flexible telehealth arrangement, we’re here to help.

The path to better ADHD management doesn’t have to be complicated. Sometimes, the right treatment is just a video call away.

References

1. FierceHealthcare – ‘DEA finalizes one-year extension of controlled substance prescribing via telehealth’ (November 2024). www.fiercehealthcare.com

2. McDermott Will & Emery (MWE) – ‘DEA Signals Extension of Telemedicine Flexibilities for Controlled Substance Prescribing for 2026’ (December 2025). www.mwe.com

3. Sheppard Mullin Healthcare Law Blog (via National Law Review) – ‘Telehealth and In-Person Visits: Tracking Federal and State Updates to Pandemic-Era Telehealth Exceptions’ (August 15, 2025). www.sheppardhealthlaw.com

4. Medical News Today – ‘Is Strattera a controlled substance?’ (January 14, 2025). www.medicalnewstoday.com

5. Center for Connected Health Policy (CCHP) – ‘Online Prescribing State Laws’ (2025). www.cchpca.org

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment